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Vascular remodeling refers to alterations in the structure of resistance vessels contributing to elevated systemic vascular resistance
in hypertension. We start with some historical aspects, underscoring the importance of Glagov’s contribution. We then move to
some basic concepts on the biomechanics of blood vessels and explain the definitions proposed by Mulvany for specific forms of
remodeling, especially inward eutrophic and inward hypertrophic.The available evidence for the existence of remodeled resistance
vessels in hypertension comes next, with relatively more weight given to human, in comparison with animal data. Mechanisms are
discussed. The impact of antihypertensive drug treatment on remodeling is described, again with emphasis on human data. Some
details are given on the three mechanisms to date which point to remodeling resistance arteries as an independent predictor of
cardiovascular risk in hypertensive patients. We terminate by considering the potential role of remodeling in the pathogenesis of
endorgan damage and in the perpetuation of hypertension.
1. Introduction
In 1987, Glagov et al. reported the surprising finding that
atherosclerotic narrowing of the arterial lumen is not simply
the result of the enlargement of atherosclerotic lesions [1].
They described that the arteries, instead of remodeling the
narrowed lumen, undergo many changes, such as increasing
the outside diameter, to preserve blood flow.
This adaptability of the arteries is essential in arterial
diseases. As with atherosclerotic coronary disease, peripheral
vascular disease andhypertensionmay be considered a failure
of the arterial wall to maintain a suitable mesh size to allow
normal blood flow.
Recently, it has been suggested that the inability to
remodel vessels properly is a way of “vascular insufficiency,”
similar to that observed in the heart during heart failure.
A definition of failure must begin with a description of the
normal mechanisms that allow the artery walls to adapt to
physiological requirements.
Hypertension elicits two different kinds of diffuse struc-
tural changes in the systemic microcirculation. One, termed
rarefaction, consists in an abnormally low spatial density
of arterioles, capillaries, and possibly venules. The other
concerns structural modifications of resistance small arteries
and arterioles, which lead to a reduction in lumen diameter
and are grouped under the generic name of remodeling. We
have recently reviewed rarefaction in detail. The focus of the
present paper is on remodeling which probably accounts for
the major part of long-term elevation of systemic vascular
resistance (SVR) in hypertensive patients [2–9].
2. Definition of Vascular Remodeling
The vascular wall is formed by endothelium cells, smooth
muscle cells, and fibroblasts interacting to form an autocrine-
paracrine complex. During vascularization, the vascular wall
detects changes in the environment, integrates these intercel-
lular communication signals, and, through the local produc-
tion of mediators, influences vascular structure and function.
Vascular remodeling is an active process of structural change
that involves changes in at least four cellular processes:
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cell growth, cell death, cell migration, and the synthesis or
degradation of extracellular matrix. Vascular remodeling is
dependent on dynamic interactions between local growth
factors, vasoactive substances, and hemodynamic stimuli
and is an active process that occurs in response to long-
standing changes in hemodynamic conditions; however, it
may subsequently contribute to the pathophysiology of vas-
cular diseases and circulatory disorders [10].
In the historical work cited previously, the increased Wof
hypertensive resistance vessels were uniformly ascribed to
a higher volume of wall material per unit length of vessel
(increased wall cross-sectional area (CSA)) or “hypertrophy.”
It was assumed that smooth muscle cells in resistance vessels
behaved as did left ventricular myocytes in the face of the
increased pressure load and that growth took place mainly
on the luminal side, leading to a structural reduction of
internal diameter. The term remodeling was first applied
to resistance vessels by Baumbach and Heistad, based on
observations made in pial arterioles from stroke-prone spon-
taneously hypertensive rats (SPSHRs), to indicate a structural
rearrangement of existing wall material around a smaller
lumen [11–13].
Mulvany proposed that vascular remodeling should
encompass any change in diameter noted in a fully relaxed
vessel, not explained by a change in transmural pressure or
compliance, and therefore due to structural factors [14–16].
To be operational, the classification necessitates appro-
priate methods for the measurement of resistance vessels
dimensions. This problem is much harder than would seem
at first sight.
To meet the definition of remodeling given previously,
the respective sizes of hypertensive and normotensive small
arteries and arterioles must be compared with the influence
of the following factors either removed or controlled for:
(i) vascular tone, (ii) transmural pressure, and (iii) vessel
compliance.
Obviously, none of these requirements would be met by
geometrical measurements made on standard histological
sections preparedwithout perfusion of the tissue sample (e.g.,
shrinking artefacts) [17, 18].
One widely used approach, possible with small arteries
(100 and 300mm), is to carry out geometrical measurements
on dissected segments put in standardized conditions in vitro.
3. Classification of Vascular Remodeling
Consideration of morphological changes has changed over
time. Feihl et al. [2] proposed a classification based on the
response to increased blood pressure. These changes are
displayed predominantly in media-to-lumen ratio (M/L),
changing the vessel wall width for increased muscle mass
(Figure 1(A)) or in the reorganization of cellular and noncel-
lular elements (Figure 1(B)). These changes increase vascular
reactivity, thus enhancing peripheral resistance. Another
mechanismmainly involves changes in the dimensions of the
lumen (Figures 1(C) and 1(D)). In this case, the restructuring
of the active components and cell signals does not result in
significant changes in the dimensions of the vascular lumen;
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Figure 1: Changes are predominantly in media-to-lumen ratio
(M/L), changing the vessel wall width for increased muscle mass
(Figure 1(A)) or in the reorganization of cellular and noncellular
elements (Figure 1(B)). Another mechanism of remodeling mainly
involves changes in the dimensions of the lumen (Figures 1(C) and
1(D)). In this case, the restructuring of the active components and
cell signals does not result in significant changes in the dimensions
of the vascular lumen. Another form of vascular remodeling is
microcirculation rarefaction (Figures 1(E) and 1(F)).
the changes in vessel wall thickness are relatively small.
Clinical examples of this type of restructuring include the
dilation of vascular remodeling associated with a constantly
high blood flow (Figure 1(D)) (e.g., arteriovenous fistula)
or the loss of cellularity and extracellular matrix proteol-
ysis, resulting in the formation of an aneurysm. Equally,
a reduction in the diameter of the vascular mass results
from a long-term reduction in blood flow (Figure 1(C)).
In fact, microcirculation rarefaction (loss of the capillary
zone) is another form of vascular remodeling that promotes
hypertension and ischemic tissue. The architecture of the
vascularwall is alsomarkedly changed in response to vascular
injury (Figures 1(E) and 1(F)). Neointima forms as part of
the reparative response to injury, and its formation involves
thrombosis, migration and vascular smooth muscle cells
(VSMC) proliferation,matrix production, and the infiltration
of inflammatory cells.
Hypertension is associated with structural changes in the
resistance vessels such as reduction in lumen diameter and
increase in M/L ratio. This mode of structural change has
been called “remodeling” [19].
Structural changes in resistance vessels are described as
a rearrangement process to understand the pathogenesis of
the disease and its therapeutic approach. However, it has been
discussed that the term “remodeling” is not ideal because it is
frequently used to describe any change in the structure of the
vessel or myocardium. To avoid this difficulty, some authors
make four proposals [20].
First, the term “remodeling” is limited to situations where
there is a change in the lumen of a relaxed vessel, as measured
under standard intravascular pressure. The changes in the
characteristics of the wall material do not take into account
the change in the vascular lumen.
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Second, the process of changing the vessel wall without
changes in the amount or characteristics of the materials is
termed eutrophic remodeling. This process can be charac-
teristic of situations involving an increase in the amount of
material (hypertrophic remodeling) and those involving a
reduction in the amount of material (hypotrophic remodel-
ing).
Third, changes associated with decrease or increase in
lumen diameter should be classified as internal remodeling
and external remodeling, respectively.
Finally, the remodeling process should be quantified.
The term “remodeling index” refers to the variations of
lumen referred to as eutrophic remodeling, depending on the
changes in the wall section area.
The previous four proposals allow for accurate termi-
nology. Thus, the increase in the M/L ratio and decrease
in the lumen diameter in resistance vessels of patients with
essential hypertension without any change in the amount
of wall material are called inner eutrophic remodeling. The
decrease in the lumen diameter of the renal afferent arteriole
with a decrease in the amount of wall material is called inner
hypotrophic remodeling.
Chronic changes in hemodynamic forces structurally
alter the vascularwall. In addition, hemodynamic changes are
not the only productionmechanisms of vascular remodeling.
The inflammatory response and changes in the components
of the matrix have been suggested as important mediators in
the vascular adaptation process [21].
Figure 2 highlights schematically the adaptation of these
changes in different pathologies, including structural changes
to the intima layer that contribute to remodeling of the
vascular wall. Thus, outward remodeling compensates for
atherosclerotic plaque growth and delays the progression
of blood flow limitation during stenosis, whereas during
restenosis, intimal hyperplasia causes a narrowing of the
lumen.
In summary, vascular wall remodeling is the result of
changes in cellular and noncellular components, depending
on the disease process causing the changes. Changes in the
growth and migration of VSMC, endothelial dysfunction,
inflammatory processes, and the synthesis or degradation of
extracellular matrix components may be present during the
disease process.
4. Pathophysiology of Vascular
Remodeling in Hypertension
4.1. Hypothesis of Inflammatory and Endothelial Dysfunction.
The traditional view of atherosclerosis as a lipid storage dis-
ease is crumbling with growing evidence that inflammation is
involved during all stages, from the initial injury to the final
stage of thrombotic complications.The narrowing of the arte-
rial lumen is not necessarily a sign of myocardial infarction,
and treating narrowed blood vessels does not prolong life.
Although invasive procedures are needed in some cases, we
understand that medical treatment and lifestyle modification
(diet and physical activity) produce benefits that may result
from reductions in inflammatory processes [22].
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Figure 2: Schematic representation for the adaptation of these
changes in different pathologies, including structural changes to the
intima layer that contribute to remodeling of the vascular wall.Thus,
outward remodeling compensates for atherosclerotic plaque growth
and delays the progression of blood flow limitation during stenosis,
whereas during restenosis, intimal hyperplasia causes a narrowing
of the lumen.
Usually, endothelial cells (EC) prevent leukocyte adhe-
sion. However, the triggers of atherosclerosis can initiate
the expression of adhesion molecules on EC, mediating
leukocyte adhesion to the arterial wall. A key part of this
interaction is VCAM-1. It is likely that oxidized lipids can
induce gene expression via the pathway initiated by the
nuclear transcription factor 𝜅B (NF-𝜅B), such as IL-1𝛽 and
TNF-𝛼 [23].
This concept of vascular inflammatory disease allows a
new approach for risk stratification and treatment. Increased
levels of CAM are predictive of cardiac events and are an
independent risk factor in men with coronary disease [24].
In our previous study, we demonstrated the presence of the
endothelium as well as the products of NF-𝜅B signaling and
VCAM-1 in an experimentalmodel ofmetabolic syndrome in
hypertensive rats receiving a fructose-rich diet (FFHR) [25].
Chemokines are low molecular weight cytokines respon-
sible for mediating the maturation, differentiation, and
migration of cells involved in the inflammatory response.
In addition to this role, chemokines could promote reactive
oxygen species (ROS) production and other cytokines during
leukocyte infiltration of the vessel wall. Monocyte chemotac-
tic protein-1 (MCP-1) is a chemokine that regulates themigra-
tion and infiltration of monocytes and macrophages into
the site of inflammation. It is overexpressed in the presence
of cardiovascular risk factors, especially in atherosclerotic
lesions. Differential activation induces nuclear transcription
factors such as NF-𝜅B and AP-1, which leads to the release of
IL-6 and the proliferation of VSMC [26].
Cytokines are soluble proteins that form a complex sig-
naling network critical in the regulation of innate and adap-
tive inflammatory response. Cytokines modulate the inflam-
matory response through their influence on the growth,
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development, and activation of leukocytes and other inflam-
matory cells. TNF-𝛼 is a key mediator in systemic inflam-
mation with a significant role in the Th1 inflammatory
pathway. The activity of TNF-𝛼 is varied and includes the
production of interleukin CAM expression, cell migration
and activation, and activation of metalloproteinases (MMP)
and COX activity, promoting the procoagulant state. TNF-𝛼
is detected in endothelial cells and smooth muscle cells at all
stages of the formation of atheromatous plaques [27].
There are over 30members of the interleukin family.They
are subdivided by the similar structure or homology of the
receptor. The transformation from a vascular homeostasis
inflammatory state is influenced by an imbalance between
the proinflammatory and anti-inflammatory activities of
interleukins. The role of IL-1 includes the stimulation of
CAM, chemokines, growth factors, tissue factor, and other
cytokines. The expression levels of the receptor antagonist
IL-1Ra significantly increase in unstable angina compared
with stable angina. Decreased levels of IL-1Ra after coronary
stent placement may be linked to a low association with
recurrent ischemia [28]. IL-6 is a multifunctional cytokine
with a central role in inflammation. Elevated levels of IL-6
increase the risk of myocardial infarction and mortality in
patients with coronary heart disease [29].
IL-10 has pleiotropic properties and influences different
cell populations. Its most important role is in inflammatory
vascular disease as part of the Th2 response. The expression
of IL-10 decreases the expression of inflammatory cytokines,
decreasing the Th1 phenotype. IL-10 also decreases NF-𝜅B
signaling reducing synthesis of proinflammatory cytokines,
CAM, chemoattractants, and growth factors [30, 31].
Endothelial dysfunction in FFHR causes an increase in
the expression ofNF-𝜅B andAP-1 and the posttranscriptional
product VCAM-1. The expression of NF-𝜅B (p65) and AP-
1 (c-fos) predominates throughout the vessel wall. Increased
VCAM-1, as discussed in the literature, is a marker of vas-
cular inflammation, vascular permeability, and endothelial
dysfunction.
This experimental model produced an increased expres-
sion of several cytokines. This finding demonstrates that
the vascular bed FFHR model presents a proinflammatory
and proatherogenic microenvironment that favors vascular
remodeling. C-reactive protein (CRP) was used to evaluate
whether this local inflammatory process is also systemic and
revealed significantly increased IL-6 expression in the liver.
The potential importance of vascular wall inflammation
as a therapeutic target remains an area not yet fully explored,
where understanding the involvement of inflammatorymedi-
ators in vascular remodeling is relevant. The data suggest
that oxidative stress and the subsequent activation of genes
involved in the inflammatory process are actively involved in
organ damage at the vascular level.
4.2. Vascular Remodeling and Extracellular Matrix Metallo-
proteinases. MMPs are tools formaintaining the homeostasis
of extracellular structures. Their synthesis is induced by
cytokines as well as cell-cell and cell-matrix interactions.
Acute coronary syndromes are an example of an increase in
clinical conditions, specifically in the vulnerable region of the
plaque [32]. Exposure to oxidized low-density lipoproteins
or TNF-𝛼 induces the expression of MT3-MMP, a protease
that degrades atherosclerotic plaques and is expressed in
macrophages [33, 34].
MMPs with accessory signaling molecules can modu-
late cell-cell interactions through the activation of signal
transmission and release of cytokines and chemokines. By
these effects, accessory signalingmolecules can propagate the
inflammatory response.
4.3. Vascular Remodeling and Acute Phase Reactants. The
production of acute phase reactants is a normal physiological
response to cytokine release in acute and chronic inflamma-
tory conditions. Ultrasensitive quantification of CRP, when it
is below the detection limits of the common assay, has a very
important role in the detection of vascular inflammation and
cardiovascular risk prediction. There is evidence that CRP is
involved in atherosclerosis, especially during the early stages.
It stimulates the production of proinflammatory cytokines in
monocytes and macrophages [35] and mediates the expres-
sion of CAM, allowing for increased leukocyte adhesion and
migration.Their increased expression suppresses endothelial
nitric oxide synthase [36] and promotes a procoagulant state.
Multiple studies have determined that increases in CPR
are an independent risk factor for developing atherosclerosis.
Data from clinical studies indicate that this association is
less important when viewed in healthy subjects and controls
inflammatory markers such as IL-6 and fibrinogen [37, 38],
whereas another study identified CRP as a predictor of
diabetesmellitus independent of established risk factors. CRP
also indicated a correlation with the risk of cardiovascular
events in women with metabolic syndrome [39].
4.4. Vascular Remodeling and the Renin-Angiotensin-Aldos-
terone System. Another important pillar in the vascular
remodeling process is the RAAS [40, 41]. To evaluate its
participation, we studied the expression of AT1R and AT2R
at the vascular level. In the experimental model of FFHR,
we observed increased expression of AT1R and decreased
expression of AT2R, promoting growth, vascular hyper-
trophy, and endothelial dysfunction. The release of ROS
and initiation of vascular inflammation through different
intracellular signaling cascades foster interconnections with
other routes such as NAD(P)H oxidase and the growth factor
receptor associated with insulin (IGFR).
Figure 3 allows us to appreciate the AT1R-associated
intracellular cascades. In this experimental model, the route
associated with the satellite receptor and the IGFR subunit
associated with NAD(P)H oxidase are the most important
pathophysiological mechanisms. The FAK pathways PI3K
and JAK2 generate stimuli and trigger contraction,migration,
and cell adhesion via intranuclear promoters that synthesize
ICAM-1 and VCAM-1. EGFR and IGFR amplified pathways
are associated with cellular growth and hypertrophy as a
result of insulinogenic stimuli and permit activation of
collagenase, which modifies the extracellular matrix. Finally,
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Figure 3: Associated intracellular cascades to physiopathology of vascular remodeling. In FFHR experimental model, the route associated
with the satellite receptor and the IGFR subunit associated with NAD(P)H oxidase are the most important pathophysiological mechanisms.
Also, the oxidative stress pathway stimulated by angiotensin activates redox-sensitive inflammatorymolecules such as AP-1 andNF-𝜅B, which
amplify vascular inflammatory response.
the oxidative stress pathway stimulated by angiotensin acti-
vates redox-sensitive inflammatory molecules such as AP-
1 and NF-𝜅B, which amplify the inflammatory response
by cytokines, chemokines, and lymphokines to ultimately
induce more vascular inflammation.
Angiotensin II is the main effector of the RAAS in the
homeostatic regulation of the cardiovascular system and
in the pathogenesis of cardiovascular disease. Aldosterone
interacts with mineralocorticoid receptors (MR), causing
endothelial dysfunction, facilitating thrombosis, reducing
complacence, causing vascular hypertrophy and cardiac
fibrosis and generating pathological remodeling. Aldosterone
also induces the growth and proliferation of VSMC. A classi-
cal genomic action of aldosterone onMR is the translocation
of this Aldo-MR complex into the nucleus, where it interacts
with promoters to posttranscriptionally regulate gene and
protein expression. For this path, increased Ki-ras2A expres-
sion (small and monomeric GTP-binding protein), which is
associated with cardiac remodeling, generates fibrosis and
cell proliferation by ERK1/2 possibly [42]. Recently, some
authors have demonstrated that aldosterone stimulates EGFR
intracellularly in CHO cells. The transactivation of this
receptor has also been described as a crucial step in the
cascade of MAPK signaling activated by angiotensin II. This
pathway allows for “cross-talk” and mutual activation that
allows the development of cardiovascular injury and subse-
quent remodeling. The latter route is via “fast” activation,
which is different from genomic stimulation and stimulates
MKP-1 and Ki-generated ras2A proliferation and vascular
remodeling; this discovery explains the changes previously
observed in other studies [43].
Noting the role of aldosterone in vascular remodeling in
FFHR, we observed that chronic administration of spirono-
lactone did not change the variables of metabolic syndrome
that were partially reversed by oxidative stress. This can be
explained by the relationship between aldosterone and the
angiotensin II receptor AT1R, which sensitizes the effects and
increased the postreceptor response [41].
In summary, abundant lines of evidence indicate the
involvement of the RAAS in the pathophysiology of vascular
remodeling; our observations in experimental pathology
highlight the structural and functional changes.
In this special issue, different authors have tried to
demonstrate the involvement of different pathophysiological
mechanisms to clarify the vascular changes associated with
hypertension and metabolic syndrome.
5. Clinical Data
The most feasible possibility for quantitative structural stud-
ies of resistance vessels in humans relies on the examination
of small muscular (presumably resistance) arteries from
biopsies of subcutaneous gluteal fat carried out under local
anaesthesia. Small arteries can also be obtained from omental
fat excised at the time of abdominal surgery [12, 44–47]. The
dissected vessels are mounted in a wire or pressure myograph
and characterized with the aforementioned methodology.
Due to the invasive character of these procedures, most rele-
vant studies are of modest size, typically involving between 10
and 20 subjects per group (with a few notable exceptions 49–
51). Furthermore, untreated hypertensives are often patients
in whom medication was withdrawn for a few weeks, rather
than being newly diagnosed.
In several studies, data indicate that small subcuta-
neous arteries of nondiabetic hypertensives undergo inward
eutrophic remodeling. In contrast, it appears that diabetes on
top of essential hypertension is associated with media hyper-
trophy, without a reduction of lumen diameter as measured
in passive conditions. The same hypertrophy was also shown
by one of these studies in normotensive diabetics, supporting
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a pressure-independent effect of diabetes on resistance vessel
morphology.
Finally, the limited data available suggest that, contrary to
the essential form, hypertension secondary to renovascular
disease could promote media growth in human small subcu-
taneous arteries [48–51].
There are at least two caveats regarding the interpretation
of these clinical data. First, the extent to which they might
be contaminated by the aforementioned sampling problem is
impossible to assess. Second, the subcutaneous vasculature is
not necessarily representative of other vascular beds. There
are a few observations to mitigate the latter concern. We
may recall here the evidence of eutrophic remodeling in the
intestinal microcirculation of hypertensive patients. In addi-
tion, a positive correlation has been found in hypertensive
patients between coronary flow reserve and the M/L ratio of
subcutaneous arteries, indeed supporting that hypertensive
changes of microvascular structure were not limited to the
subcutis [52, 53]. Finally, Harazny et al. [50] have very
recently been able to evaluate the vascular remodeling of
retinal arterioles in patients with treated hypertension and
without advanced retinopathy (stage III or IV). To that effect,
they used laser Doppler imaging whereby outer and inner
diameters were, respectively, determined from reflection and
perfusion images. Results indicated a higher ratiowhen blood
pressure control was poorer than when it was satisfactory.
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